| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3269350 | HPB | 2013 | 7 Pages |
Abstract
The literature does not support the routine use of cetuximab as the standard firstâline treatment of colorectal liver metastases, rather highlighting the need for the optimization of treatment on an individual basis, especially depending on tumour KRAS status.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Claire Jones, Mark A. Taylor, Billy McWilliams,